GluN2B-selective antagonists like radiprodil (Figure 11), traxoprodil, and ifenprodil improve PD motor symptoms, increase antiparkinsonian efficacy of dopaminergic agents synergistically, and lower L-DOPA-induced dyskinesia [147], supporting the suggestion that the glutamatergic system may elicit anti-parkinsonian effects if properly manipulated. Here, GRIN2B is linked to Parkinson disease.